Pasithea Therapeutics Corp has reported encouraging pharmacokinetic data for its PAS-004 tablet in an ongoing Phase 1/1b trial involving adult NF1 patients.
The tablet formulation of PAS-004 shows linear pharmacokinetics with a dose-proportional increase in exposure, achieving a Cmax/Cmin ratio of less than 2. This indicates improved predictability and reduced variability compared to the capsule formulation.
In the ongoing studies, the 4mg and 8mg tablet cohorts demonstrated significant pharmacokinetic parameters, with the 8mg tablet showing higher exposure levels than the 22mg capsule, suggesting enhanced efficacy for treating neurofibromatosis type 1-associated plexiform neurofibromas.
PAS-004 has a long half-life of approximately 57 hours, supporting once-daily dosing and potentially contributing to its therapeutic effectiveness in patients with symptomatic and inoperable plexiform neurofibromas.
Wall Street analysts forecast KTTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KTTA is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast KTTA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KTTA is 3.00 USD with a low forecast of 3.00 USD and a high forecast of 3.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.853
Low
3.00
Averages
3.00
High
3.00
Current: 0.853
Low
3.00
Averages
3.00
High
3.00
H.C. Wainwright
Sara Nik
Buy
initiated
$3
2025-12-08
Reason
H.C. Wainwright
Sara Nik
Price Target
$3
AI Analysis
2025-12-08
initiated
Buy
Reason
H.C. Wainwright analyst Sara Nik initiated coverage of Pasithea Therapeutics with a Buy rating and $3 price target. The firm says the company has a next-generation MEK inhibitor "set to tackle both orphan and oncology markets." The analyst views Pasithea's pipeline as being the "best-in-class comprehensive attack" on the MAPK pathways, potentially yielding access to a $20B potential market in multiple indications.
About KTTA
Pasithea Therapeutics Corp. is a biotechnology company focused on the discovery, research, and development of treatments for central nervous system (CNS) disorders and other diseases. The Company is advancing a pipeline of three therapeutic product candidates, with a focus on its lead product candidate, PAS-004, a macrocyclic mitogen-activated protein kinase, or MEK inhibitor. PAS-004 is a small molecule allosteric inhibitor of MEK 1 and 2 (MEK 1/2) for potential use in the treatment of a range of RASopathies, including neurofibromatosis type 1 (NF1) and a number of oncology indications, among others. Its remaining two programs, PAS-001 and PAS-003, are in the earlier stages of development and are based on novel targets for the treatment of CNS disorders that it believes address limitations in the treatment paradigm of the indications it plans to address, which are amyotrophic lateral sclerosis (ALS) for its PAS-003 program, and schizophrenia for its PAS-001 program.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
